Casablanca – Morocco is preparing a first round of medicine price reductions covering nearly 300 products, with retail prices expected to fall by between 10% and 70%. The measure comes as the country begins implementing a new framework for regulating medicine prices, after years of debate over the cost of treatment and the financial burden placed on patients and health insurance schemes.

The first list of medicines has been approved by the Ministry of Health and Social Protection, according to information provided by ministry sources. The exact products and their new retail prices have not yet been publicly detailed, but the reductions are expected to vary considerably depending on the medicine concerned.

The planned cuts represent the first major practical application of a reform adopted this year to change how medicine prices are calculated and reviewed in Morocco. The new framework was introduced through Decree No. 2.25.631, issued in July and published in the Official Gazette in August. It replaces important elements of the pricing mechanism that had been in force since 2013.

For Moroccan households, the issue has a direct impact on healthcare access. The cost of medicines can become particularly difficult for patients requiring long-term treatment, especially when several products are prescribed at the same time or when medicines are not fully covered by health insurance. The financial burden can also increase for treatments used for chronic conditions, where spending is repeated over months or years.

The new reform changes the frequency with which prices are reviewed. Under the previous framework, medicine prices were generally subject to longer review periods. The new system provides for a review every three years, allowing authorities to adjust prices more regularly in response to international benchmarks and changes in market conditions.

Another important change concerns the international comparison used to establish Moroccan medicine prices. For medicines with an ex-factory price excluding taxes above about $31, the new rules use the lowest price recorded in designated reference countries as the benchmark. For medicines priced at about $31 or less at the ex-factory level, the average of the reference prices continues to be used.

This approach is particularly relevant for more expensive medicines. Instead of relying on an average of prices observed abroad, the authorities can use the lowest reference price when the product exceeds the specified threshold. The objective is to create greater scope for reductions where international price differences are significant.

The reform also changes the economics surrounding imported medicines by reducing the import margin from 10% to 2.5%. This is intended to contribute to lower final prices while changing the way different components of the medicine price are calculated.

The first group of nearly 300 medicines is not expected to be the end of the process. The new framework calls for medicines already marketed in Morocco to undergo a broader review within 12 months of the new rules taking effect. This creates the possibility of additional lists of products receiving price reductions over the coming months.

The scale of the potential savings has attracted attention because medicine expenditure represents a significant cost for both households and Morocco’s health insurance system. Earlier analysis of the reform estimated that changes affecting an initial segment of medicines could generate savings of up to roughly $68 million a year, although the eventual financial impact will depend on the medicines covered, the size of the reductions and the implementation of the new system.

The affordability question is not new. Research examining medicine price revisions carried out between 2014 and 2019 found that reductions affected 1,704 medicines across different therapeutic categories. The study found that the reductions varied widely: some medicines experienced only very small changes, while a small number recorded reductions exceeding 70%. The research also concluded that price revisions alone were unlikely to resolve all barriers to access to medicines.

This historical experience illustrates why the current reform is being watched beyond the initial headline figure of nearly 300 medicines. A percentage reduction does not necessarily translate into the same level of savings for every patient. The effect depends on the original price of the medicine, how frequently it is used, whether it is reimbursed, and the reimbursement base applied by the health insurance system.

For example, a 20% reduction on a relatively inexpensive medicine will produce a much smaller saving than the same percentage reduction on a high-priced treatment. Conversely, even a modest reduction on a medicine used regularly can accumulate into a meaningful annual saving for households.

The expansion of mandatory health insurance has added another dimension to the debate. As coverage expands, the cost of reimbursed medicines becomes increasingly relevant to the financial management of the system. Lower medicine prices can potentially reduce expenditure for insurance funds while also lowering the amount that insured patients have to pay when reimbursement does not cover the entire retail price.

The reform is therefore designed around several objectives at the same time: reducing medicine prices, improving access to treatment, limiting patient out-of-pocket spending and controlling health insurance expenditure.

The government has also linked the pricing changes to the development of Morocco’s pharmaceutical sector and greater national capacity in medicine production. A pricing system that lowers costs for patients while maintaining incentives for local manufacturers and ensuring the availability of essential products must balance several interests, including affordability, supply security, investment and competition.

The availability of lower-cost generic medicines is another factor in the affordability debate. Analysts have pointed to the relatively strong presence of branded medicines and the scope for greater use of generics as part of the broader discussion about reducing treatment costs. The question is not limited to the price of individual products, but also concerns how medicines are prescribed, reimbursed, distributed and made available to patients.

The first 300 medicines will therefore provide an early indication of how the new pricing mechanism works in practice. Their final retail prices, once officially communicated, will show the direct effect of the first round of revisions on consumers.

The broader test will come with the planned review of medicines already marketed in Morocco within the first year of the new framework. If the process results in sustained reductions across a wider range of products, it could alter the cost of treatment for households and the financial burden carried by the health insurance system.

At the same time, medicine affordability will continue to depend on factors beyond regulated retail prices, including reimbursement levels, generic substitution, household income, availability of products and the cost of long-term treatment. The current reform addresses the pricing mechanism, while the wider challenge of ensuring affordable and consistent access to medicines involves several parts of Morocco’s healthcare system.

For now, the planned reductions of up to 70% for nearly 300 medicines mark the first significant stage in the implementation of the new pricing framework. Further reviews expected within the next 12 months will determine how broadly the changes extend across Morocco’s medicine market and how much of the financial pressure on patients and health insurance schemes can ultimately be reduced.